Sentences with phrase «with myxomatous mitral valve disease»
16 Tidholm A, Ljungvall I, Hoglund AB, Westling AB, Haggstrom J. Tissue Doppler and Strain Imaging in Dogs with Myxomatous Mitral Valve Disease in Different Stages of Congestive Heart Failure.
http://www.scielo.br/ Not exact matches
In the QUEST Study, pimobendan significantly increased the survival time of dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD).
Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST Study.
To determine whether chronic oral administration of pimobendan in dogs with evidence of increased heart size secondary to preclinical myxomatous mitral valve disease (MMVD) can delay the onset of clinical signs of congestive heart failure (CHF).1
In the VetSCOPE Study, pimobendan rapidly improved the quality of life in dogs with CHF caused by myxomatous mitral valve disease (MMVD).
Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study — A Randomized Clinical Trial.
Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC Study - a randomized clinical trial.
The EPIC Study showed a significant benefit in administering pimobendan in dogs with preclinical myxomatous mitral valve disease (MMVD)-- before the onset of congestive heart failure (CHF) cardiac - related death, or euthanasia (composite primary endpoint).
This groundbreaking study sought to answer a key question: Can pimobendan — with proven efficacy in treating dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD)-- also delay the onset of CHF caused by MMVD?
The EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly) Study1 analysed whether long - term administration of pimobendan to dogs with stage B2 myxomatous mitral valve disease (MMVD) and echocardiographic and radiographic evidence of cardiac enlargement will delay onset of clinical signs of congestive heart failure (CHF), cardiac - related death, or euthanasia (composite primary endpoint).
The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD).
The trial, titled «Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease (MMVD) and Cardiomegaly» (EPIC), is the largest clinical study ever to be conducted in veterinary cardiology.
The licence for Vetmedin (Boehringer Ingelheim) has been extended to cover dogs with asymptomatic myxomatous mitral valve disease (MMVD).
Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.